1. Home
  2. ADPT vs NBHC Comparison

ADPT vs NBHC Comparison

Compare ADPT & NBHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADPT
  • NBHC
  • Stock Information
  • Founded
  • ADPT 2009
  • NBHC 2009
  • Country
  • ADPT United States
  • NBHC United States
  • Employees
  • ADPT N/A
  • NBHC N/A
  • Industry
  • ADPT Biotechnology: Biological Products (No Diagnostic Substances)
  • NBHC Major Banks
  • Sector
  • ADPT Health Care
  • NBHC Finance
  • Exchange
  • ADPT Nasdaq
  • NBHC Nasdaq
  • Market Cap
  • ADPT 1.4B
  • NBHC 1.4B
  • IPO Year
  • ADPT 2019
  • NBHC 2012
  • Fundamental
  • Price
  • ADPT $10.38
  • NBHC $35.85
  • Analyst Decision
  • ADPT Strong Buy
  • NBHC Hold
  • Analyst Count
  • ADPT 7
  • NBHC 5
  • Target Price
  • ADPT $10.57
  • NBHC $46.80
  • AVG Volume (30 Days)
  • ADPT 1.3M
  • NBHC 183.9K
  • Earning Date
  • ADPT 07-31-2025
  • NBHC 07-22-2025
  • Dividend Yield
  • ADPT N/A
  • NBHC 3.22%
  • EPS Growth
  • ADPT N/A
  • NBHC N/A
  • EPS
  • ADPT N/A
  • NBHC 2.89
  • Revenue
  • ADPT $189,527,000.00
  • NBHC $389,883,000.00
  • Revenue This Year
  • ADPT $24.46
  • NBHC $12.13
  • Revenue Next Year
  • ADPT $20.25
  • NBHC $6.96
  • P/E Ratio
  • ADPT N/A
  • NBHC $12.45
  • Revenue Growth
  • ADPT 8.61
  • NBHC N/A
  • 52 Week Low
  • ADPT $2.99
  • NBHC $32.83
  • 52 Week High
  • ADPT $10.87
  • NBHC $51.76
  • Technical
  • Relative Strength Index (RSI)
  • ADPT 62.28
  • NBHC 42.54
  • Support Level
  • ADPT $9.90
  • NBHC $35.52
  • Resistance Level
  • ADPT $10.85
  • NBHC $37.93
  • Average True Range (ATR)
  • ADPT 0.48
  • NBHC 0.61
  • MACD
  • ADPT -0.02
  • NBHC -0.13
  • Stochastic Oscillator
  • ADPT 68.39
  • NBHC 13.69

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

About NBHC National Bank Holdings Corporation

National Bank Holdings Corp is a bank holding company. It provides various banking products and financial services to commercial, business, and consumer clients in the United States. The company offers deposit products including checking accounts, savings accounts, money market accounts, and other deposit accounts, including fixed-rate and fixed-maturity time deposits. It also provides commercial and industrial loans and leases. In addition, it offers treasury management solutions comprising online and mobile banking, commercial credit cards, wire transfers, automated clearing house, and electronic bill payments.

Share on Social Networks: